Page 149 - 南京医科大学学报自然科学版

第41卷第9期 楼伊慧，孙 晋，李天女. 正电子显像剂在乳腺癌诊疗中的应用进展［J］.
2021年9月 南京医科大学学报（自然科学版），2021，41（09）：1411-1415 ·1415 ·

18
form specificity F⁃fluorofuranylnorprogesterone for mea⁃ HER2 expression in breast carcinoma［J］. J Nucl Med，
suring progesterone receptor protein response to estradiol 2016，57（1）：27-33
challenge in breast cancer［J］. J Nucl Med，2019，60（2）：220 ［28］ SKOVGAARD D，PERSSON M，BRANDT⁃LARSEN M，
［17］ PAQUETTE M，TURCOTTE E. Measuring estrogen recep⁃ et al. Safety，dosimetry，and tumor detection ability of
tor functionality using progesterone receptor PET imag⁃ （68）Ga⁃NOTA⁃AE105：first⁃in⁃human study of a novel ra⁃
ing：rising to the（estradiol）challenge［J］. J Nucl Med， dioligand for uPAR PET imaging［J］. J Nucl Med，2017，

2018，60（2）：jnumed.118.220921 58（3）：379-386
［18］ ZHAO H，MENG H，WEN J，et al. Noninvasive classifica⁃ ［29］ LIU H，SUN H，ZHANG B，et al.（18）F⁃FDG PET imag⁃
tion of human triple negative breast cancer by PET imag⁃ ing for monitoring the early anti⁃tumor effect of albenda⁃
ing with GRP78⁃targeted molecular probe［（68）Ga］DO⁃ zole on triple⁃negative breast cancer［J］. Breast Cancer，
TA⁃VAP［J］. Mol Imaging Biol，2020，22（3）：772⁃779 2020，27（3）：372-380
［19］ DEHDASHTI F，LAFOREST R，GAO F，et al. Assess⁃ ［30］ MANDELIN J，CARDÓ⁃VILA M，DRIESSEN W H，et al.
ment of progesterone receptors in breast carcinoma by Selection and identification of ligand peptides targeting a
PET with 21⁃18F⁃fluoro⁃16α，17α⁃［（R）⁃（1’⁃α⁃furylme⁃ model of castrate⁃resistant osteogenic prostate cancer and
thylidene）dioxy］⁃19⁃norpregn⁃4⁃ene⁃3，20⁃dione［J］. J their receptors［J］. Proc Natl Acad Sci U S A，2015，112
Nucl Med，2012，53（3）：363-370 （12）：3776-3781
［20］ GAO F，PENG C，ZHUANG R，et al.（18）F⁃labeled ethis⁃ ［31］ MORGENROTH A，TINKIR E，VOGG A，et al. Targeting
terone derivative for progesterone receptor targeted PET of prostate ⁃ specific membrane antigen for radio ⁃ ligand
imaging of breast cancer［J］. Nucl Med Biol，2019，72⁃73： therapy of triple⁃negative breast cancer［J］. Breast Cancer
62-69 Res，2019，21（1）：116
68
［21］ CHAN S R，FOWLER A M，ALLEN J A，et al. Longitudi⁃ ［32］ PASSAH A，ARORA S，DAMLE N，et al. Ga⁃prostate⁃
nal noninvasive imaging of progesterone receptor as a pre⁃ specific membrane antigen PET/CT in triple ⁃ negative
dictive biomarker of tumor responsiveness to estrogen de⁃ breast cancer［J］. Clin Nucl Med，2018，43（6）：460-461
privation therapy［J］. Clin Cancer Res，2015，21（5）： ［33］ ARSLAN E，ERGÜL N，KARAGÖZ Y，et al. Recurrent
1063-1070 brain metastasis of triple negative breast cancer with high
68
［22］ BOERS J，VENEMA C M，DE VRIES E，et al. Serial uptake in Ga ⁃ PSMA ⁃ 11 PET/CT［J］. Clin Nucl Med，
［（18）F］⁃FDHT⁃PET to predict bicalutamide efficacy in 2021，46（2）：e106-e108
patients with androgen receptor positive metastatic breast ［34］LINDNER T，LOKTEV A，ALTMANN A，et al. Develop⁃
cancer［J］. Eur J Cancer，2021，144：151-161 ment of quinoline⁃based theranostic ligands for the target⁃
［23］ MODI S，SAURA C，YAMASHITA T，et al. Trastuzumab ing of fibroblast activation protein［J］. J Nucl Med，2018，
deruxtecan in previously treated HER2 ⁃ positive breast 59（9）：1415-1422
18
68
cancer［J］. N Engl J Med，2020，382（7）：610-621 ［35］ PANG Y，ZHAO L，CHEN H. Ga⁃FAPI outperforms F⁃
［24］DEHDASHTI F，WU N，BOSE R，et al. Evaluation of［（89） FDG PET/CT in identifying bone metastasis and peritone⁃
Zr］trastuzumab⁃PET/CT in differentiating HER2⁃positive al carcinomatosis in a patient with metastatic breast can⁃
from HER2⁃negative breast cancer［J］. Breast Cancer Res cer［J］. Clin Nucl Med，2020，45（11）：913-915
Treat，2018，169（3）：523-530 ［36］ MOON E S，ELVAS F，VLIEGEN G，et al. Targeting fibro⁃
［25］ GEBHART G，LAMBERTS L E，WIMANA Z，et al. Mo⁃ blast activation protein（FAP）：next generation PET radio⁃
lecular imaging as a tool to investigate heterogeneity of ad⁃ tracers using squaramide coupled bifunctional DOTA and
vanced HER2 ⁃ positive breast cancer and to predict pa⁃ DATA（5m）chelators［J］. EJNMMI Radiopharm Chem，
tient outcome under trastuzumab emtansine（T⁃DM1）：the 2020，5（1）：19
ZEPHIR trial［J］. Ann Oncol，2016，27（4）：619⁃624 ［37］ BALLAL S，YADAV M P，KRAMER V，et al. A theranos⁃
［26］ MCKNIGHT B N，VIOLA ⁃ VILLEGAS N T. Monitoring tic approach of［（68）Ga］Ga ⁃ DOTA.SA.FAPi PET/CT ⁃
Src status after dasatinib treatment in HER2+ breast can⁃ guided［（177）Lu］Lu⁃DOTA.SA.FAPi radionuclide thera⁃
cer with（89）Zr ⁃ trastuzumab PET imaging［J］. Breast py in an end⁃stage breast cancer patient：new frontier in
Cancer Res，2018，20（1）：130 targeted radionuclide therapy［J］. Eur J Nucl Med Mol Im⁃
［27］ KEYAERTS M，XAVIER C，HEEMSKERK J，et al. Phase aging，2021，48（3）：942-944
68
I study of Ga⁃HER2⁃nanobody for PET/CT assessment of ［收稿日期］ 2021-03-17